BCSC
Breast Cancer Surveillance Consortium: Working together to advance breast cancer research
 
Home   |   Data   |   Statistics   |   Tools   |   Collaborations   |   Work with Us   |   Publications   |   About   |   Links

Benchmarks for Cancers by Indication for Examination for 714,984 Diagnostic Mammography Examinations from 1996 - 2005 --- based on BCSC data as of 2007*

You are viewing the 2007 collection of this data. Data from other times are also available:
  Work-Up of Abnormal Screening Examination Short-Interval Follow-Up Evaluation of Breast Problem/ No Lump or Lump Unknown Evaluation of Breast Problem/ Palpable Lump All Diagnostic Examinations
Sensitivity** 89.5 59.8 75.9 87.8 83.1
Readers with 5+ cancers 213 59 103 202 347
True Positives 6,751 709 2,469 5,233 17,532
Cancers 7,540 1,185 3,251 5,962 21,109
Sensitivity (Median-50th percentile) 89.5 62.5 75.3 88.4 82.8
Sensitivity (25th, 75th percentiles) 83.1, 94.7 52.9, 71.9 68.4, 83.3 81.8, 93.2 75, 88.7
Sensitivity (10th, 90th percentiles) 76.2, 100 42.9, 80 58.3, 91.7 71.1, 100 68.6, 92.9
Specificity 88.7 96.9 95.7 92.2 93.2
Readers with 100+ non-cancers 314 274 278 231 479
True Negatives|| 149,388 131,249 148,838 78,809 542,775
Non-cancers# 168,438 135,468 155,597 85,487 582,193
Specificity (Median-50th percentile) 89.2 97.2 96.3 93.2 93.5
Specificity (25th, 75th percentiles) 84.9, 92 95.3, 98.4 93.8, 97.8 89.9, 95.4 90.9, 95.6
Specificity (10th, 90th percentiles) 79.2, 94 92.9, 99 91.3, 98.8 85.9, 97.1 88.1, 97.2

Notes

Numbers are frequencies unless otherwise indicated. 58161 (7.4%) examinations were given an initial BI-RADS assessment of zero. The first non-zero assessment within 180 days was used as the final assessment for analysis. Examinations without a non-zero assessment within 180 days were excluded (26414,3.3%).

* Includes examinations for radiologists with minimum numbers of cases in a given column as designated; excludes examinations for which the radiologist is unknown.

** Sensitivity = the percentage of cancers that had an abnormal interpretation (BI-RADS category 4 or 5).

True Positive = the number of cancers that had an abnormal interpretation (BI-RADS category 4 or 5).

Cancers = the number of examinations with a tissue diagnosis of cancer within 1 year following the examination.

Specificity = the percentage of non-cancers that had a negative interpretation (BI-RADS category 1, 2, or 3).

|| True Negative = the number of non-cancers that had a negative interpretation (BI-RADS category 1, 2, or 3).

# Non-cancers = the number of examinations without a tissue diagnosis of cancer within 1 year following the examination.

Table numbers last updated September 19, 2007. The following source must be cited when reproducing this table: NCI-funded Breast Cancer Surveillance Consortium co-operative agreement (U01CA63740, U01CA86076, U01CA86082, U01CA63736, U01CA70013, U01CA69976, U01CA63731, U01CA70040). Downloaded xx/xx/xxxx from the Breast Cancer Surveillance Consortium Web site - http://breastscreening.cancer.gov/statistics/benchmarks/diagnostic/2007/table7.html

[Return to Performance Benchmarks for Diagnostic Mammography]